News and Trends 9 Aug 2022 Mersana Therapeutics announces collaboration with GSK for the co-development of cancer treatment A global collaboration was announced today (August 9) between Mersana Therapeutics Inc and GSK plc that will give GSK the option to co-develop and commercialize an antibody drug conjugate (ADC). The ADC called XMT-2056 is designed to activate the innate immune system through STING signaling in both tumor-resident immune cells and in tumor cells. Anna […] August 9, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 9 Aug 2022 Study says gene editing with CRISPR/Cas9 can lead to cell toxicity and genome instability CRISPR/Cas9 is a commonly used gene editing technique. CRISPR allows the introduction of a desired DNA sequence into (virtually) any spot of the genome, thus modifying or inactivating a gene. The technique is widely used in biomedical research and some CRISPR-based therapies are in clinical trials for the treatment of human blood disorders, some types […] August 9, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 9 Aug 2022 Formulations of Arecor Therapeutics’ drug to treat inflammatory diseases granted patents Formulations of a drug that can help a number of inflammatory diseases including rheumatoid arthritis and Crohn’s disease have been issued patents by the European Patent Office (EPO). The EPO issued two patents that will protect Arecor Therapeutics’ formulations of high-concentration adalimumab until 2038. The company made the announcement today (August 9). Monoclonal antibody Adalimumab, […] August 9, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 9 Aug 2022 Pfizer and Valneva to start phase 3 Lyme disease vaccine study Pfizer Inc. and Valneva SE have initiated a phase 3 clinical study, Vaccine Against Lyme for Outdoor Recreationists (VALOR), to investigate the efficacy, safety and immunogenicity of their investigational Lyme disease vaccine candidate, VLA15. “With increasing global rates of Lyme disease, providing a new option for people to help protect themselves from the disease is […] August 9, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 8 Aug 2022 Positive trial results for schizophrenia drug, KarTX, from PureTech’s founded entity, Karuna Therapeutics Positive topline results from a phase 3 trial looking at the effect of a drug to treat schizophrenia were announced today (August 8). Karuna Therapeutics Inc, the founded entity of PureTech Health plc, said results from the EMERGENT-2 trial evaluating the efficacy, safety and tolerability of KarXT (xanomeline-trospium) in adults met its primary endpoint and […] August 8, 2022 - 4 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
Opinion 8 Aug 2022 Building a healthtech industry in Europe to serve patients By Maryvonne Hiance, president of HealthTech For Care; and Christian Pierret, Former Minister Delegate for Industry The HealthTech For Care endowment fund, launched by France Biotech is designed to support and promote access to care for all and, more specifically, to new medical technologies and drugs. Europe is just emerging from a health crisis that […] August 8, 2022 - 5 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 8 Aug 2022 Lung cancer trial patients responding well to combination treatment offered by HUTCHMED and AstraZeneca A medication used to treat non-small cell lung carcinomas (NSCLC) with specific mutations has demonstrated a 49% objective response rate (ORR) in patients. AstraZeneca and HUTCHMED announced that TAGRISSO Plus Savolitinib – a third generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor – was helping patients with high levels of mesenchymal epithelial transition (MET). […] August 8, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 8 Aug 2022 Dallas College gets $8.8M grant to grow biotech workforce in North Texas Dallas College has been awarded a U.S. Economic Development Administration grant to help underserved communities access living-wage jobs in biotechnology. The college noted biotech is a sector poised to grow exponentially with the need for additional highly skilled employees in North Texas, according to the latest labor market intelligence. With approximately $8.8 million in funds […] August 8, 2022 - 5 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 8 Aug 2022 HUTCHMED drug in colorectal cancer trial meets primary endpoint A trial to look at the use of a drug targeting refractory metastatic colorectal cancer (CRC) has met its primary endpoint of overall survival (OS) in patients with the disease. China’s HUTCHMED Limited announced today (August 8) that the phase 3 FRESCO-2 trial investigating the use of fruquintinib had met all secondary endpoints too. The […] August 8, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 8 Aug 2022 Epigenic Therapeutics raises $20M for gene editing technology Epigenic Therapeutics Co., Ltd., a Chinese biotech gene editing company, has secured $20 million in Series Angel and Pre-A funding. The Series Pre-A funding came from investments by Morningside Venture Capital, Kingray Capital, Trinity Innovation Fund and TigerYeah Capital. Angel investor FountainBridge Capital is also participating. The proceeds will be used to advance the company’s […] August 8, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 8 Aug 2022 Genmab and BioNTech expand collaboration to develop and commercialize immunotherapy candidates A collaboration between Genmab and BioNTech to develop and commercialize immunotherapies for the treatment of cancer patients has been expanded. Under the expansion announced today (August 5), the companies will jointly work to research, develop, and commercialize novel monospecific antibody candidates for various cancer indications. Since 2015, the companies have been working on the joint […] August 8, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 8 Aug 2022 Allogenic immune cell therapies to be developed as three groups join forces Three entities have joined forces to develop allogenic immune cell therapies based on a platform that generates functionally mature immune cells from induced pluripotent stem cells (iPSCs). ElevateBio LLC is a technology-driven company focused on powering transformative cell and gene therapies. It announced recently (August 5) that it has formed a yet-to-be-named company co-founded by […] August 8, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email